#CTSO

Zacks Small Cap Research

@zackssmallcap.bsky.social

2 months ago

#CTSO: CytoSorbents Price Target Increased to $5.00 Based on Higher Than Expected Gross Margins buff.ly/8xeFDUu

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

3 months ago

#CTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00 buff.ly/20ySDCO

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update CytoSorbents (NASDAQ: CTSO) reported Q3 2025 revenue of $9.5M, up 10% year-over-year, with gross margin 70%. Operating loss improved to $2.9M and net loss was $3.2M ($0.05/share); adjusted net loss was $2.6M ($0.04/share). Cash and equivalents were $9.1M on Sept 30, 2025, proforma $11.6M assuming an additional $2.5M term loan.The company amended its credit agreement to provide an immediate $2.5M term loan, extended interest-only to Dec 31, 2026, and issued 1,428,571 warrants at $0.70. Workforce reduction of ~10% and a restructuring charge up to $900k aim to reach operating cash-flow breakeven in Q1 2026. DrugSorb-ATR De Novo submission is planned in Q1 2026 with an anticipated decision by mid-2026.

#CTSO CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

Reach Higher Montana

@reachhighermontana.bsky.social

5 months ago

Career and Technology Student Organizations (CTSOs) help thousands of Montana students each year with leadership development, career preparation, networking, and skill development.

#CTSO #CareerAndTechnologyStudentOrganizations #Leadership #SkillDevelopment #CareerPrep #Networking

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

First Randomized Trial Data: CytoSorbents' DrugSorb-ATR Shows Success in Urgent Cardiac Surgery Safety CytoSorbents presents groundbreaking RCT data for DrugSorb-ATR in DOAC removal and CytoSorb efficacy in bleeding reduction at EACTS 2025. Features two key studies and expert symposium.

#CTSO CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

CytoSorbents Corporation to Showcase Innovations at H.C. Wainwright 27th Annual Global Investment Conference CytoSorbents Corporation is set to present at the H.C. Wainwright Conference, showcasing advancements in blood purification technology for critical care and surgery.

CytoSorbents Corporation to Showcase Innovations at H.C. Wainwright 27th Annual Global Investment Conference #United_States #New_York #CytoSorbents #Blood_Purification #CTSO

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

6 months ago

#CTSO: Announces the De Novo denial on DrugSorb-ATR was upheld by the FDA. However, a Path to Approval Was Also Provided by the Agency. buff.ly/P3rFtuo

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

FDA Opens New Path Forward: CytoSorbents' Breakthrough Device for Critical Heart Surgery Patients Shows Safety FDA upholds DrugSorb-ATR De Novo denial but confirms device safety and proposes new authorization pathway. Device aims to help urgent CABG surgery patients on ticagrelor avoid bleeding risks.

#CTSO CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

7 months ago

#CTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00. buff.ly/F4MM9we

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update CytoSorbents (NASDAQ: CTSO) reported Q2 2025 financial results showing revenue growth of 9% to $9.6 million compared to Q2 2024, primarily driven by 22% growth in Germany. The company achieved a net income of $1.9 million ($0.03 per share) versus a net loss in Q2 2024, while maintaining a gross margin of 70.9%.Key developments include an FDA appeal hearing for DrugSorb™-ATR, with a final regulatory decision expected in 2025, and continued work with Health Canada following their Notice of Refusal. The company's cash position stands at $11.7 million as of June 30, 2025. Management expects to approach breakeven operations by the end of 2025 through improved execution and cost control measures.The company announced an upcoming World Sepsis Day Global Webinar on September 10, 2025, highlighting CytoSorb's role in treating sepsis and septic shock, supported by recent positive clinical studies and meta-analyses showing significant mortality reduction.

#CTSO CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Breakthrough Sepsis Treatment: CytoSorb Therapy Achieves 70% Survival Rate in Latest Clinical Studies Major clinical studies reveal CytoSorb blood purification therapy significantly improves septic shock survival rates. See groundbreaking results from 744-patient analysis.

#CTSO CytoSorbents Leads a New Era in Sepsis Treatment

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

Market Wire News

@marketwirenews.com

8 months ago

NEWS: ( NASDAQ: #CTSO ) PRISM Mid-Day Movers: Commercial Momentum for MedDevices Boosts Index

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping down in trading Wed Jul 2nd - #VCIG #SVRE #BGLC #MESO #CYCC #CTSO #CRIS #BV - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Critical FDA Appeal Date Set for Revolutionary Cardiac Surgery Blood Purification Device FDA schedules crucial appeal hearing while Health Canada review continues for breakthrough cardiac surgery device. Final decisions expected by year-end. See timeline details.

#CTSO CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

FDA Appeal: CytoSorbents Fights for Revolutionary Blood Purification Device After Denial Critical blood purification device for CABG surgery patients faces new regulatory pathway. Senior FDA officials to review breakthrough designation case. Learn timeline.

#CTSO CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025 CytoSorbents Corporation (NASDAQ: CTSO) presented new real-world data at EuroPCR 2025 demonstrating significant benefits of their blood purification technology. The study compared 150 patients from the STAR Registry using CytoSorbents' device to 644 control patients during urgent CABG surgery while on ticagrelor. Key findings showed remarkable reductions in bleeding complications: BARC-4 severe bleeding (10.7% vs 33%, p

#CTSO CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

9 months ago

#CTSO: CytoSorbents Reports Strong 1st Quarter 2025 Results buff.ly/2GKh8ub

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

CytoSorbents Slashes Q1 Losses by 75% While FDA Appeal Process Advances for Breakthrough Device Q1 highlights: Net loss drops to $0.02/share, $6.8M rights offering completed, FDA appeal strategy for DrugSorb-ATR unveiled. See full financial details.

#CTSO CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

10 months ago

#CTSO: CytoSorbents provides regulatory update for DrugSorb-ATR. buff.ly/lizTXzU

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

CytoSorbents Lands $1.7M Strategic Funding: New DrugSorb Product Launch and Manufacturing Expansion Ahead Fresh $1.7M funding fuels DrugSorb-ATR commercialization and Princeton facility expansion. Non-dilutive capital strengthens growth initiatives. Get details.

#CTSO CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

Zacks Small Cap Research

@zackssmallcap.bsky.social

11 months ago

#CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. buff.ly/nd1faKQ

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights CytoSorbents (NASDAQ: CTSO) reported strong Q4 2024 results with product revenue of $9.2M, up 25% from Q4 2023. Full-year 2024 product revenue reached $35.6M, a 15% increase year-over-year, with 71% product gross margins.Q4 operating loss improved 61% to $3.7M, while net loss was $7.6M ($0.14/share). The company strengthened its balance sheet through a successful Rights Offering, raising $7.3M in net proceeds.Key developments include FDA's acceptance of DrugSorb-ATR De Novo application and submission to Health Canada, with regulatory decisions expected in 2025. The company reported strong international growth with 28% increase in direct sales outside Germany and 22% growth in Distributor/Partner sales, though German sales remained flat.Management expects Q1 2025 product sales to decline modestly due to German sales team restructuring, but anticipates improved results in H2 2025 as they work toward breakeven in core business.

#CTSO CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

CytoSorbents Q4 Revenue Jumps 25% Despite Earnings Delay - Key Metrics Released CytoSorbents reports preliminary Q4 revenue up 25% to $9.2M amid audit completion. Strong 70% gross margins and $17M pro-forma cash position signal robust fundamentals.

#CTSO CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants CytoSorbents announced the exercise of 1,417,208 Series A Right Warrants at $1.13 per share, generating $1.6 million in gross proceeds. This follows a previous Rights Offering, bringing total gross proceeds to $7.85 million, including $6.25 million raised on January 10, 2025. The company now has approximately $12.3 million in net liquidity, post-offering fees.The exercise price was based on 90% of the 5-day volume-weighted average price of $1.2589 per share, with a cap of $2.00. Shareholders, including management and the Board, exercised these warrants and will receive shares along with a refund of $0.87 per warrant.Additionally, CytoSorbents is progressing with its DrugSorb-ATR marketing applications with the FDA and Health Canada, expecting regulatory decisions in 2025. The company also highlighted the availability of approximately 4.8 million shares for the exercise of Series B Right Warrants, which expire on April 10, 2025, with an exercise price range of $2.00 to $4.00.

#CTSO CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #CTSO ) CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

CytoSorbents Expands Global Reach with Strategic Dubai Hub for Middle East & Africa Growth CytoSorbents launches new sales subsidiary in Dubai Science Park, establishing a strategic gateway to serve growing medical technology demands across Middle East and Africa markets.

#CTSO CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai

www.stocktitan.net/news/CTSO/cyto-sorbents-...

0 0 0 0